Harmony Biosciences (HRMY) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zymeworks (ZYME) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 8.8% versus a loss of 5.0%. Over five years, ZYME leads with a +34.1% price change compared with -13.2% for HRMY. Harmony Biosciences is the larger company by market cap ($1.91 billion vs $1.81 billion), about 1.1 times the size, while Zymeworks is growing revenue faster (+38.9% vs +21.5%).
On valuation, Harmony Biosciences trades at a lower forward P/E (5.4x vs 55.0x for Zymeworks). Harmony Biosciences converts more of its revenue into profit, with a net margin of 18.3% versus -76.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | ZYME |
|---|---|---|
| Share price | $32.59 | $26.14 |
| Market cap | $1.91B | $1.81B |
| 1-day change | -1.18% | -2.68% |
| YTD return | -12.91% | -0.72% |
| 1-year return | -5.01% | +8.83% |
| 5-year return | -13.21% | +34.05% |
| P/E ratio (TTM) | 10.79 | 49.32 |
| Forward P/E | 5.37 | 54.95 |
| EPS (TTM) | $3.02 | $0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | $105.97M |
| Revenue growth (YoY) | +21.51% | +38.87% |
| Net income (latest FY) | $158.69M | $-81.13M |
| Gross margin | 77.16% | — |
| Operating margin | 24.00% | -87.34% |
| Net margin | 18.27% | -76.56% |
| 52-week high | $43.49 | $31.97 |
| 52-week low | $25.90 | $21.52 |
| Distance from 52-week high | -25.06% | -18.24% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +47.53% | +65.61% |
| Average volume | 1.01M | 1.09M |
| Shares outstanding | 58.72M | 68.70M |
| Employees | 293 | 279 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed HRMY by 13.8 percentage points over the past year.
- Zymeworks trades at a higher earnings multiple (49.3x vs 10.8x trailing P/E).
- Harmony Biosciences is more profitable, keeping 18.3 cents of every revenue dollar as net income versus -76.6 cents for Zymeworks.
- Zymeworks grew revenue faster in its latest fiscal year (+38.87% vs +21.51%).
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees
HRMY vs ZYME FAQ
Which is bigger, Harmony Biosciences or Zymeworks?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $1.91B compared with $1.81B for Zymeworks (ZYME).
Which stock has performed better over the past year, HRMY or ZYME?
ZYME returned +8.83% over the past 12 months, compared with -5.01% for HRMY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HRMY or ZYME?
HRMY has the lower trailing P/E at 10.8, versus 49.3 for ZYME. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Harmony Biosciences and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.